Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network - sprookjes - yvandenbroek - TriplyDB

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network

http://www.wikidata.org/entity/Q34163024

about

Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer The many ways to make a luminal cell and a prostate cancer cell Does Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.Phosphorylation-induced Conformational Ensemble Switching in an Intrinsically Disordered Cancer/Testis Antigen.NF-κB and androgen receptor variant expression correlate with human BPH progression Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia Isolation and analysis of discreet human prostate cellular populations NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.Analysis of gene expression profile identifies potential biomarkers for atherosclerosis.Inflammatory mediators in the development and progression of benign prostatic hyperplasia.Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate.Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target.

P2860

Q26748530-85B85798-8FF6-4611-A53F-58EBE42E234C Q26797386-7CF939B4-3A48-4C7B-AADA-7FBE10CBAF0E Q36059979-37B1843C-1C2D-421B-9EA0-912AAFD5FECD Q36139918-68FD4C61-89CD-44EA-815F-8C8ADE47D33B Q36606285-F4E6D75B-E1E0-443A-A0BE-4FB78810221B Q36625094-09E2594D-B184-4B75-926F-C6A40CA06581 Q36863464-3D5389E3-6750-4F48-A576-07B7999E2521 Q37018606-F284A148-938E-499C-9A2F-FFFE3B9A6B59 Q37297560-BC79E93F-287E-40E3-B78B-072778D3AE50 Q38968019-E768A219-638B-4098-B4F7-738AA12F3EA4 Q47591866-7C91530B-46C3-4DCE-B220-679D67095744 Q48048218-18089FFE-F98A-4798-9F10-D5E887A58829 Q53106730-31D112CC-05A9-4589-9250-070B491ECB0E Q55515702-103664C8-66C0-411E-968D-E2204D06D393

P2860

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network

http://www.wikidata.org/entity/Q34163024

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Surgical intervention for symp ...... 1 transcription factor network

@ast

Surgical intervention for symp ...... 1 transcription factor network

@en

Surgical intervention for symp ...... 1 transcription factor network

@nl

type

label

Surgical intervention for symp ...... 1 transcription factor network

@ast

Surgical intervention for symp ...... 1 transcription factor network

@en

Surgical intervention for symp ...... 1 transcription factor network

@nl

prefLabel

Surgical intervention for symp ...... 1 transcription factor network

@ast

Surgical intervention for symp ...... 1 transcription factor network

@en

Surgical intervention for symp ...... 1 transcription factor network

@nl

P1433

Q34163024-CEC4934B-D63C-4DE5-97F4-10B44C5BEC27

P1476

Q34163024-814BE0A4-9B32-4AE3-BADE-046565BBF170

P2093

Q34163024-20DF3C8B-503B-420B-9F20-DB6083CB897F

Q34163024-4A2A2642-441D-48F0-8B2B-6B63EFC651C2

Q34163024-82E5A7CB-0558-4AC8-9235-5CE4F4BF7FD5

Q34163024-E6CA068F-5707-46F5-BA1E-10C9D270D7B8

Q34163024-F0831F4D-AA97-4BBF-B2AC-3E6244E4C9D1

P2860

Q34163024-0DB6F1F8-7F53-42F7-9940-A50C3AACE7C7

Q34163024-121EA18A-2702-4DC0-983F-0952BA82F29A

Q34163024-14A40F16-8C67-40CF-B50C-F00A55680EA2

Q34163024-1643BBC6-1508-4931-ADC4-9FA8FCF8E04C

Q34163024-166ED2C5-6E01-47F0-962E-7AB57B29C10C

Q34163024-1D60FEF6-6D16-40AE-9831-F68F87A0860B

Q34163024-492BBEF4-A157-45E3-BA08-753FD5CF49E4

Q34163024-522C8711-9A88-4916-BBE3-84684890FD96

Q34163024-528FEBB6-043A-46B9-A450-5588D87C5D80

Q34163024-55B46C9A-C498-4F24-9304-1B869F17036E

P304

Q34163024-D330DC30-4E79-4BF2-BC60-49D71A0128F0

P31

Q34163024-D4074B64-4DF6-43EF-BB57-6D1B65C65848

P356

Q34163024-D2CB173F-5D95-4712-97B2-9A9DDFE6261B

P433

Q34163024-649DE29D-A548-4496-88D3-A2C608AA7A8C

P478

Q34163024-96BDC5AC-60A7-4406-9CFD-F8E053BFB563

P50

Q34163024-29018880-69BB-414A-BE6A-EE60EE1D0B0C

Q34163024-A3C008F1-0E2C-48DE-9CF8-1A1639EFC620

P577

Q34163024-19695095-98E9-4363-AC98-CB41295126AC

P5875

Q34163024-C22963BA-B705-4BDE-8BD8-06326224C4A7

P698

Q34163024-58F24E3E-DFC5-4180-AFB9-D7A6E256D9EE

P932

Q34163024-2EDDDA4D-10E5-4B3B-9E84-2E69DBA5DCE3

P356

P1433

P1476

Surgical intervention for symp ...... 1 transcription factor network

@en

P2093

Jay H Fowke

http://www.w3.org/2001/XMLSchema#string

Nicole L Miller

http://www.w3.org/2001/XMLSchema#string

Omar Hameed

http://www.w3.org/2001/XMLSchema#string

Opal Lin-Tsai

http://www.w3.org/2001/XMLSchema#string

Peter E Clark

http://www.w3.org/2001/XMLSchema#string

P2860

The regulation of AP-1 activity by mitogen-activated protein kinases

AP-1: a double-edged sword in tumorigenesis

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the Comb

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

DNA binding of the glucocorticoid receptor is not essential for survival.

CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis.

P304

669-679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.22785

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Simon W. Hayward

Douglas W. Strand

P577

2014-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260117571

http://www.w3.org/2001/XMLSchema#string

P698

24500928

http://www.w3.org/2001/XMLSchema#string

P932

4160824

http://www.w3.org/2001/XMLSchema#string